Please login to the form below
pediatrics
This page shows the latest pediatrics news and features for those working in and with pharma, biotech and healthcare.
Morning brief: Herzuma launched in Europe, rare disease status for Orchard candidate and more
Orchard gains rare disease status for ex-GSK therapy. Orchard Therapeutics has been granted an FDA Rare Pediatric Disease Designation for its rare disease gene therapy candidate OTL-200, which it
Latest news
-
Dr Reddy's brings its generics portfolio to France
Meanwhile, in its home country it is targeting a number of therapy areas, having agreed a 118m deal with UCB in 2015 to acquire a portfolio of dermatology, respiratory and pediatric
-
Lilly pilots enhanced online trial information
The pilot project has so far been added to two clinical trials, a study of Taltz (ixekizumab) in non-radiographic axial spondyloarthritis and one of Cialis (tadalafil) in pediatric patients with
-
Biogen buys into Ionis' nusinersen after positive phase III trial
Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months”
-
Celebrating excellence
The programme saw Novo work in partnership with Roche, the International Society for Pediatric and Adolescent Diabetes (ISPAD) and the World Diabetes Foundation (WDF).
-
PMEA 2015 win for Novo's Changing Diabetes in Children
The programme saw Novo work in partnership with Roche, the International Society for Pediatric and Adolsecent Diabetes (ISPAD) and the World Diabetes Foundation (WDF).
More from news
Approximately 1 fully matching, plus 23 partially matching documents found.
Latest Intelligence
-
Implementing eHealth innovation
The first results from the global, five-year observational study in children with growth disorders was presented at the 10th International Meeting of Pediatric Endocrinology in September 2017.
-
Paging Dr Millennial
Almost 50% of the world's population today is under 25 years old, which means that family planning, women's health and pediatrics will be growing elements of the world's
-
Pharma deals in August 2015
In 2012 the PRV programme was extended to include rare pediatric diseases and the emergence of trading in PRVs was noted in our last annual Deal Watch report.
-
Pharma deals during November 2014
In 2012 the PRV programme was extended to include rare pediatric diseases. ... BioMarin was awarded a Rare Pediatric Disease PRV when it received approval of Vimizim, a new biological product for patients with Mucopolysaccharidosis type IVA.
-
Pharma deals during March 2013
825. Edison Pharmaceuticals/ Dainippon Sumitomo. Licence. EPI-743 (orphan pediatric mitochondrial disease) and EPI-589 (adult CNS disease) (phase II).
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
BMS appoints oncology development head
As a trained pediatric oncologist, Fouad brings to this role exceptional clinical experience and an unwavering commitment to patients.
-
Dr Andrew Mulberg moves from FDA to Amicus Therapeutics
Dr Mulberg is a pediatric gastroenterologist, and was attending physician and fellowship director in gastroenterology and hepatology for The Children's Hospital of Philadelphia between 1993 and 2001. ... He is currently the board chairman and member of
-
Former PEPFAR head Mark Dybul to lead the Global Fund
In addition to his new post, Dr Dybul currently serves as a director on several executive and advisory boards of health organisations, including Malaria No More, the Elizabeth Glaser Pediatric AIDS
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Mastering the precision medicine opportunity
Last year the FDA made a pioneering move in this space and approved Keytruda for use in adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Business Director
-
Competitive Salary Offered
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Account Director, Medical Education
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Senior Medical Writer
-
Salary TBC
-
Associate Director
-
£75, 000-90, 000
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Global Business Development Director – Health Education
-
excellent commission
-
Medical Writer
-
Salary TBC
-
Senior Account Manager
-
Competitive Salary Offered
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Account Manager / Account Director
-
Competative
-
Account Director
-
Competitive Salary Offered
Subscribe to our email news alerts
- FDA adcomm split on Sanofi’s type 1 diabetes drug
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
- Evenity back on track with FDA panel blessing in osteoporosis
- NICE gives Lilly’s Verzenios chance to compete with rivals
- J&J’s Erleada cleared for early prostate cancer in Europe
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Quick links
Infographics
